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chitosan-coated solid-lipid nanoparticles
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Abstract 
Background: The overall goal of this study was to demonstrate potential chemopreventive effects of ferulic acid (FA), 
an antioxidant, combined with aspirin (ASP), a commonly used anti-inflammatory drug for pancreatic cancer chemo-
prevention, using a novel chitosan-coated solid lipid nanoparticles (c-SLN) drug delivery system encapsulating FA and 
ASP.
Results: Our formulation optimization results showed that c-SLNs of FA and ASP exhibited appropriate initial particle 
sizes in range of 183 ± 46 and 229 ± 67 nm, encapsulation efficiency of 80 and 78 %, and zeta potential of 39.1 and 
50.3 mV, respectively. In vitro studies were conducted to measure growth inhibition and degree of apoptotic cell 
death induced by either FA or ASP alone or in combination. Cell viability studies demonstrated combinations of low 
doses of free FA (200 µM) and ASP (1 mM) significantly reduced cell viability by 45 and 60 % in human pancreatic can-
cer cells MIA PaCa-2 and Panc-1, respectively. However, when encapsulated within c-SLNs, a 5- and 40-fold decreases 
in dose of FA (40 µM) and ASP (25 µM) was observed which was significant. Furthermore, increased apoptosis of 
35 and 31 % was observed in MIA PaCa-2 and Panc-1 cells, respectively. In vivo studies using oral administration 
of combinations of 75 and 25 mg/kg of FA and ASP c-SLNs to MIA PaCa-2 pancreatic tumor xenograft mice model 
suppressed the growth of the tumor by 45 % compared to control, although this was not statistically significant. In 
addition, the immunohistochemical analysis of tumor tissue showed significant decrease in expression of proliferation 
proteins PCNA and MKI67, and also increased expression of apoptotic proteins p-RB, p21, and p-ERK1/2 indicating the 
pro-apoptotic role of the regimen.
Conclusion: Combination of FA and ASP delivered via a novel nanotechnology-based c-SLN formulation demon-
strates potential for pancreatic cancer chemoprevention and could be a promising area for future studies.
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Background
Cancer of the pancreas is the fourth leading cause of can-
cer in the US affecting about 44,000 Americans each year. 
It has become increasingly apparent that despite more 
than 20 years of intensive research on treatment, the sur-
vival rate continues to be a dismal <5 % within 5 years of 
diagnosis [1]. Current treatment modalities are largely 
ineffective, thus bringing to the forefront the develop-
ment of alternative strategies to tackle this disease [2]. 
A viable strategy could be the use of chemopreventive 
agents to suppress, delay or even reverse the onset of the 
disease [3–5]. Our group has been interested in the use 
of novel chemopreventive agents and their combinations 
for pancreatic cancer prevention. Recently, we have also 
demonstrated the importance of delivering these agents 
using novel nanotechnology-based drug delivery systems 
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wherein high efficacy has been achieved at very low doses 
[3, 6–9].
Pancreatic carcinoma arises from a heterogeneous 
molecular pathogenesis involving several oncogenic 
pathways and defined genetic mutations. In the last few 
years, however, oxidative stress and inflammation have 
emerged as important risk factors in pancreatic carcino-
genesis [10–13]. The reports on the role of reactive oxy-
gen species (ROS) in tumor initiation have proved that 
oxidative stress acts as a DNA-damaging agent, effec-
tively increasing the mutation rate within cells and thus 
promoting oncogenic transformation [14]. Additionally, 
oxidative stress acts by further recruiting inflammatory 
cells to the site of damage and producing more reactive 
species. This sustained inflammatory/oxidative environ-
ment leads to a loop effect, which can damage healthy 
neighboring epithelial and stromal cells and over a pro-
longed time period lead to carcinogenesis [15]. Based 
on this information, the hypothesis of this study was to 
combine chemopreventive agents ferulic acid (FA) and 
aspirin (ASP) encapsulated in c-SLNs for the synergistic 
chemoprevention of pancreatic cancer.
FA is one of the most abundant antioxidants found 
in plants. FA has a high antioxidant potential due to its 
resonance-stabilized phenoxyl radical structure, allowing 
it to be an effective scavenger of free radicals to show its 
anti-cancer effects [16]. Recently many researchers have 
focused their attention on the anti-cancer activity of FA 
on skin, colon, liver and breast cancers [17–19]. However, 
no other group has investigated its potential in pancreatic 
cancer chemoprevention. Non-steroidal anti-inflamma-
tory drugs (NSAIDs) such as ASP are currently the best 
studied chemopreventive agents for many cancers, and 
have been demonstrated to modulate the NF-κB pathway 
[20]. Clinical studies associated with the long term use of 
ASP for pancreatic cancer prevention, however, have met 
with mixed results thus far [21–23]. Given these conflict-
ing reports on the use of ASP in pancreatic cancer but, 
simultaneously, realizing the proven benefits of ASP as a 
chemopreventive in cancer, it reaffirms the need for fur-
ther study of this drug in pancreatic cancer prevention.
Solid-lipid nanoparticles (SLNs) were developed over a 
decade ago but have never before been considered exten-
sively for chemoprevention of pancreatic cancer. For the 
current study, we are proposing a novel SLN delivery sys-
tem coated with chitosan (c-SLN). Our previous research 
in chitosan-based drug delivery systems combined with 
the current research on SLNs enables us to design an 
effective hybrid system for chemoprevention. Chitosan is 
a nontoxic, biodegradable and biocompatible polysaccha-
ride derived from the shells of crustaceans, with proven 
in vivo safety profile [24, 25]. c-SLNs are biodegradable, 
bioadhesive and have permeation enhancing properties 
thus acting as promising vehicles for oral drug delivery 
with wide range of pharmaceutical applications [26]. The 
primary amino group in chitosan offers some special 
properties such as water-solubility, hemocompatibility, 
and cationic groups which could react with a big num-
ber of anions or other negatively charged molecules [27]. 
And also based on the cationic property, chitosan-based 
nanoparticles exhibit a mucoadhesive feature because of 
their positive charge, thereby capable of prolonging their 
residence time in the negatively charged epithelia in small 
intestine [28], thus increasing the drug concentration at 
the site of absorption. Moreover, chitosan can mediate 
the opening of tight junctions between neighboring epi-
thelial cells reversibly, facilitating the paracellular trans-
port of drug molecules ultimately leading to improved 
bioavailability of the drugs [29]. Thus, c-SLN combines 
the advantages of SLN with the biological properties of 
chitosan as a drug delivery vehicle.
In this study, we have used a novel c-SLN technology 
for the oral delivery of combinations of FA and ASP for 
pancreatic cancer to evaluate their combined chemopre-
ventive efficacy in two different human pancreatic cancer 
cells, MIA PaCa-2 and Panc-1. Additionally, a pancreatic 
tumor xenograft mouse model was used to determine the 
efficacy of the chemopreventive regimen.
Results
Physical characterization of FA and ASP encapsulated 
c‑SLNs
Based on the methodology described earlier [3, 9], c-SLNs 
of FA and ASP exhibited initial particle sizes in the nanom-
eter range of 183 ± 46 and 229 ± 67, respectively. All the 
c-SLNs showed optimal particle size with low variability. 
The c-SLNs exhibited 80 and 78 % encapsulation efficiency 
of the FA and ASP respectively within the lipid nanopar-
ticles. The zeta potential of FA particles were −8.0 and 
39.1  mV before and after coating with chitosan, respec-
tively. The surface charge on ASP nanoparticles were 
−6.0 and 50.3 mV before and after coating with chitosan, 
respectively. The polydispersity index (PDI) was 0.25 and 
0.19 for FA and ASP c-SLN, respectively (Table 1).
In vitro evaluation of FA and ASP drug release from c‑SLNs
The ability of nanoparticles to deliver drugs was exam-
ined by determining the drug release in PBS solution (pH 
6.8) and acidic conditions (pH 1.6), as shown in Fig.  1. 
The percentage of drug released from c-SLN was plot-
ted as a function of time. The release of the drug from 
nanoparticles prepared using stearic acid as lipid was 
conducted over a period of 96 h. As shown in Fig. 1a, the 
release of FA in PBS solution was faster compared to ASP 
at initial time point up to 12 h. A cumulative drug release 
of approximately 98 % of ASP was observed within 48 h 
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of the study, and then showed constant release up to 96 h. 
The FA c-SLN showed approximately 98  % drug release 
at 72 h, even though it showed a faster release pattern in 
initial time points compared to ASP. Both the formula-
tions exhibited slow sustained release of the drug. The 
release profile was similar in acidic condition at pH 1.6 
compared to PBS solution at pH 6.8 (Fig. 1b).
Determination of IC50 concentration of free and c‑SLN 
encapsulated FA and ASP
In order to evaluate the combined effects of FA and ASP on 
pancreatic cancer, we first treated MIA PaCa-2 and Panc-1 
cells with various individual concentrations (5–5000 µM) 
of FA and ASP for 72 h, and cell growth was measured by 
the MTS assay. Our observations show that there was a 
dose-dependent inhibition of the growth of MIA PaCa-2 
and Panc-1 cells. In case of MIA PaCa-2, the IC50 values 
for FA and ASP observed were 1.7 and 2.6  mM, respec-
tively (Fig. 2a); whereas in Panc-1 cells, the IC50 values for 
FA and ASP were 1.9 and 2.4 mM, respectively (Fig. 2b).
As shown in Fig.  2, cell viability assay was performed 
with serial dilutions (1–1000 µM) of FA and ASP c-SLN 
nanoparticle formulations. In MIA PaCa-2 cells, the 
IC50 concentrations for FA c-SLN, ASP c-SLN, and blank 
c-SLN observed were 81.15, 34.66, and 362 μM, respec-
tively (Fig. 2c); whereas in Panc-1 cells, the IC50 values for 
FA c-SLN, ASP c-SLN, and blank c-SLN were 66.6, 58.32, 
and 341.8 µM respectively (Fig. 2d).
Effect of the combination of FA and ASP c‑SLN 
on pancreatic cancer cells
To examine the effect of combined regimen on cell pro-
liferation, MIA PaCa-2 and Panc-1 cells were treated 
with low and ineffective concentrations of free form FA 
(200 μM) and ASP (1 mM) for 72 h. As shown in Fig. 3a, 
single agents did not show significant change in cell 
viability at these concentrations. However, when used 
in combination at identical concentrations, FA  +  ASP 
showed a significant effect with a reduction in cell viabil-
ity of MIA PaCa-2 cells by as much as 45  % (P  <  0.01), 
whereas FA + ASP combination in Panc-1 cells showed a 
remarkable decrease of 60 % (P < 0.001) cell viability.
In case of c-SLNs, after determining the dose response 
curves individually and obtaining the IC50 value for FA 
and ASP c-SLNs, ineffective and low concentrations were 
selected for FA c-SLN (40 µM) and ASP c-SLN (25 µM) 
showing minimal inhibitory response on the cell lines 
(Fig. 3b). When combined together (FA + ASP c-SLNs), 
the cell viability was reduced to 70 % for MIA PaCa-2 and 
Panc-1 cells, respectively (P < 0.001). Thus, the combina-
tion of FA and ASP c-SLN administered at low concen-
trations showed a significant reduction in cell viability 
compared to unmodified, free form combinations of FA 
and ASP. The blank c-SLN at same concentration did not 
show reduction in cell viability, hence demonstrating that 
c-SLN formulation excipient has no significant effect on 
cell viability of pancreatic cancer cells (Fig. 3b).
Table 1 Particle size and encapsulation efficiency of drug loaded chitosan-solid lipid nanoparticles
c-SLN chitosan solid lipid nanoparticle
Drug Particle size (nm) Encapsulation efficiency (%) Zeta potential (mV) Polydispersity index (PDI)
Ferulic acid c-SLN 183 ± 46 80 39.1 ± 3.4 0.25 ± 0.06
Aspirin c-SLN 229 ± 67 78 50.3 ± 7.3 0.19 ± 0.05
Fig. 1 In vitro drug release from chitosan solid lipid nanoparticle (c-SLN). a In vitro drug release from c-SLNs over a period of 96 h in phosphate 
buffered saline (PBS), pH 6.8; and b in vitro drug release from c-SLNs over a period of 96 h in acidic medium, pH 1.6. The drug release was analyzed 
using a HPLC system
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FA and ASP combination induces apoptosis in pancreatic 
cancer cells
The induction of apoptosis was measured by flow cytome-
try for all individual drugs and their combinations on MIA 
PaCa-2 and Panc-1 cells. Individual concentrations of FA 
c-SLN (40 µM) and ASP c-SLN (25 µM) showed minimal 
apoptotic cells (data not shown). In case of MIA PaCa-2 
cells (Fig.  3c), FA and ASP c-SLN combinations demon-
strated approximately 35  % apoptotic cells (P  <  0.01). In 
case of Panc-1 cells (Fig. 3d), c-SLN combined FA + ASP 
showed 31  % of apoptotic cells (P  <  0.01). Overall, our 
studies confirmed that FA + ASP combinations were sig-
nificantly effective in inducing apoptosis of cancer cells.
FA and ASP combination modulates proliferation proteins 
in pancreatic cancer cells
From our previously published studies, aspirin was 
reported to modulate proliferation proteins and ERK 
pathway [6, 7], hence we wanted to determine whether 
the proliferation proteins like PCNA, MKI67, RB and 
ERK1/2 are involved in growth inhibition. The MIA 
PaCa-2 and Panc-1 protein lysates were analyzed by west-
ern blot analysis. We observed that incubation of MIA 
PaCa-2 and Panc-1 cells with combination FA  +  ASP 
inhibits PCNA and MKI67 proteins, and produced 
higher phosphorylation of ERK1/2 and RB proteins com-
pared with the control and individual drugs (Fig. 3e).
FA and ASP c‑SLN in a pancreatic xenograft tumor model
In vivo studies using a xenograft mouse model was sub-
sequently conducted to determine whether oral adminis-
tration of FA + ASP c-SLN combinations could suppress 
the growth of pancreatic tumor. MIA PaCa-2 cells were 
implanted subcutaneously in SCID mice. The treatment 
by oral gavage started 1 day after tumor implantation and 
continued as per protocol for 5  weeks (Fig.  4a). The FA 
and ASP c-SLN were administered at the dose of 75 and 
25 mg/kg daily via oral gavage. During the experiment, all 
mice were monitored to investigate possible adverse effects 
caused by drug treatment. The FA and ASP c-SLN treat-
ment did not cause any significant weight loss of the mice 
(Fig.  4b). These results suggested that no noticeable side 
Fig. 2 Dose dependent inhibition of cell viability in pancreatic cancer cells. a, c MIA PaCa-2 and b, d Panc-1 cells were treated with unmodified 
ferulic acid (FA), unmodified aspirin (ASP), FA encapsulated in chitosan-solid lipid nanoparticles (c-SLNs), and ASP c-SLNs. MTS assay was performed 
to determine the cell viability of MIA PaCa-2 and Panc-1 cells after treating with a range of concentrations of free and c-SLN modified FA and ASP 
for 72 h. The IC50 values were then determined using nonlinear regression using graph pad prism software. Each data point represents the mean 
percent viable cells measured in three parallel but independent experiments
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effects or toxicity were caused by the treatment regimen. 
Furthermore, no gross signs of toxicity were observed dur-
ing visible inspections of general appearance and macro-
scopic examinations of individual organs.
In an effort to establish the efficacy of a combined 
therapy compared with single-agent treatment, we 
determined the mean tumor volume in all treated 
groups. For instance, at day 36 the mean tumor vol-
ume (mean ± SEM) in control and blank c-SLN (vehicle 
control) mice were 2576  ±  530 and 2513  ±  352  mm3 
respectively, as compared with 2235  ±  244  mm3 in FA 
c-SLN and 2713 ± 736 mm3 in ASP c-SLN treated mice. 
However, mean tumor volume in FA + ASP c-SLN group 
was 1424 ± 402 mm3 (Fig. 4c). The administration of FA 
and ASP c-SLN combination treatment resulted in 45 % 
reduction in the mean tumor volume compared with 
vehicle control group, though this reduction was statisti-
cally non-significant.
Fig. 3 Synergistic effect of ferulic acid (FA) and aspirin (ASP) combination on cell viability and apoptosis. MTS assay was performed to determine 
the cell viability of a free FA + ASP and b chitosan-solid lipid nanoparticle (c-SLN) encapsulated FA + ASP combination. MIA PaCa-2 and Panc-1 cells 
were treated with free FA (200 µM), with ASP (1 mM) and c-SLN FA (40 µM) with c-SLN ASP (25 µM) individually and in combination for 72 h. Each 
bar represents the mean percent viable cells measured in three parallel but independent experiments. c MIA PaCa-2 and d Panc-1 cells were treated 
with c-SLN encapsulated FA (40 µM) with c-SLN ASP (25 µM) for 48 h and stained with Annexin V-PI apoptosis detection kit. e Panc-1 cells were 
treated with FA (40 µM) with c-SLN ASP (25 µM) alone or in combination for 24 h. The expression of PCNA, MKI67, phospho-RB, and phospho-ERK1/2 
proteins were evaluated by western blot analysis. The equal loading was confirmed by using an anti-β-actin antibody. Statistical significance was 
determined by one-way ANOVA followed by Dunnett’s multiple comparison test post hoc analysis. ***P < 0.001 represents statistical significance of 
differences between control and treatment group
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FA and ASP inhibits expression of proliferation markers 
in pancreatic tumor tissues
In order to evaluate the effect of FA +  ASP chemopre-
ventive regimens on tumor cell proliferation, immuno-
histochemistry (IHC) was performed to measure the 
expression of cell proliferation markers proliferating cell 
nuclear antigen (PCNA; Fig. 5a, c) and MKI67 (Fig. 5b, d) 
on pancreatic tissues. The protein expression was evalu-
ated by IHC scores as described in the methods section. 
The results in Fig. 5 showed that FA c-SLN in combina-
tion with ASP c-SLN showed 46 and 43 % down-regula-
tion in the expression of PCNA and MKI67 proliferation 
proteins respectively in tumor tissues compared with 
the blank c-SLN control group (p  <  0.001). Together, 
our results suggest that FA and ASP c-SLN combina-
tion treatment down regulates expression of proliferation 
proteins.
FA and ASP c‑SLN combination inhibits apoptotic and cell 
cycle proteins in pancreatic tumor tissues
Important families of proteins that are involved in the 
regulation of apoptosis are mammalian mitogen activated 
protein kinases (MAPK) that can be subdivided in extra-
cellular signal-regulated kinases (ERKs) that regulate cell 
growth and differentiation [30, 31]. Also anti-carcino-
genic effect of FA has been linked to down-regulation of 
an anti-apoptotic p21 protein [32]. Based on this infor-
mation, we evaluated the expression of phosphorylated 
retinoblastoma (p-RB) protein, phospho-ERK1/2 and 
p21 protein expression using IHC. As shown in Fig.  6, 
the FA  +  ASP c-SLN combination group showed 220 
and 178 % up-regulation of p21 and p-RB proteins com-
pared to vehicle control, which are anti-apoptotic and 
tumor suppressor protein, respectively. The FA  +  ASP 
c-SLN treatment group also showed 363 % upregulation 
D-1 D-2 D-35 D-36 
Vehicle 
Ferulic acid c-SLN 
Aspirin c-SLN 







Fig. 4 In vivo effect of ferulic acid (FA) and aspirin (ASP) c-SLNs on MIA PaCa-2 xenograft SCID mice. a Flow chart representation of experimental 
design for in vivo studies. b Body weight variations of xenograft SCID mice during the FA and ASP c-SLNs treatment period. Average body weight 
transitions of mice over the 35 days treatment period. c Average tumor growth of pancreatic cancer cells MIA PaCa-2 over a period of 35 d after 
treatment. FA and ASP c-SLNs were administered via oral gavage for 35 days. Statistical significance was determined by one-way ANOVA followed 
by Dunnett’s multiple comparison test post hoc analysis
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of p-ERK1/2 protein compared to vehicle control, which 
correlated with our published chemoprevention studies 
of ASP combinations, suggests activation of p-ERK1/2 as 
a mechanism of action of ASP [6].
Discussion
Pancreatic carcinoma arises from a heterogeneous 
molecular pathogenesis involving several oncogenic 
pathways and defined genetic mutations. Studies have 
Fig. 5 Effect of ferulic acid (FA) and aspirin (ASP) chemopreventive regimen on tumor cell proliferation and apoptosis. Immunohistochemical 
analysis was performed on paraffin-embedded and micro-sectioned pancreatic tissues as described in methods section. a, b Representative images 
showing effect of modified FA and ASP c-SLN combination on PCNA and MKI67 (marker of proliferation Ki-67) expressions in pancreatic tissue. c, d 
A significant decrease in the PCNA and MKI67 expression was observed in modified FA + ASP treatment groups compared to blank c-SLN vehicle 
control group. All the pictures were taken at ×200 magnification. Statistical significance was determined by one-way ANOVA followed by Dunnett’s 
multiple comparison test post hoc analysis. *p < 0.05; ***p < 0.001 represents statistical significance between blank c-SLN vehicle control and 
FA + ASP c-SLN treatment
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suggested that chronic oxidative stress, particularly 
from chronic inflammation, is associated with car-
cinogenesis [33, 34]. For example, ulcerative colitis has 
long been linked with high incidence of colorectal can-
cer; and chronic gastrititis, such as from infection with 
H. pylori, has been associated with a high incidence of 
gastric cancer [35, 36]. Recent studies have shown an 
important role for ROS in tumor development [37, 38]. 
ROS can be produced from endogenous sources, such 
as from mitochondria, peroxisomes, and inflammatory 
cell activation [34, 39]; and exogenous sources, including 
environmental agents. This oxidative stress then, in turn, 
may cause DNA, protein, and/or lipid damage, leading 
to changes in chromosome instability, genetic muta-
tion, and/or modulation of cell growth that may result in 
cancer. The potential outcomes of oxidative stress occur 
when not counter-balanced by antioxidant defenses of 
the cell.
Previous studies in literature show the uptake of SLNs 
from the intestinal lymphatic system thus bypassing first 
pass metabolism in the liver, increasing circulation time, 
reducing dosage and ensuring high bioavailability of the 
Fig. 6 Effect of ferulic acid (FA) and aspirin (ASP) chemopreventive regimen on apoptotic proteins. Immunohistochemical analysis was performed 
on paraffin-embedded and micro-sectioned pancreatic tissues as described in methods section. a–c Representative images showing effect of 
modified FA and ASP c-SLN combination on p-RB, p21, and p-ERK1/2 protein expressions in pancreatic tissue, respectively. d–f An increase in the 
p-RB, p21 and p-ERK1/2 protein expressions was observed in FA + ASP c-SLN treated groups compared to the vehicle control group. All the pictures 
were taken at ×200 magnification. Statistical significance was determined by one-way ANOVA followed by Dunnett’s multiple comparison test post 
hoc analysis. ***p < 0.001 represents statistical significance between blank c-SLN vehicle control and FA + ASP c-SLN treatment
Page 9 of 14Thakkar et al. Cell Biosci  (2015) 5:46 
drugs [40–43]. The addition of chitosan also provides 
steric stabilization of nanoparticles thus reducing their 
uptake by the reticulo-endothelial (RES) system in the 
blood [44, 45]. Moreover, chitosan can mediate the open-
ing of tight junctions between epithelial cells reversibly, 
facilitating the paracellular transport of drug molecules 
ultimately leading to improved bioavailability of the 
drugs [29]. Thus, c-SLN combines the advantages of SLN 
with the biological properties of chitosan as a drug deliv-
ery vehicle.
The effect of FA and ASP was initially evaluated by 
calculating the IC50 values and then by combining the 
ineffective concentrations to exhibit an additive or syner-
gistic effect against the pancreatic cancer cells proving to 
be more efficacious at lower concentrations. When free 
FA and ASP were combined at ineffective concentrations 
of 200 μM and 1 mM respectively, showed 45–60 % inhi-
bition of cell growth. The cell viability assay on FA and 
ASP entrapped c-SLNs was carried out using FA (40 µM) 
and ASP (25 µM) as individual concentrations. Individu-
ally, they showed little or no decrease in the cell viabil-
ity, but when combined, a significant reduction by 70 % 
was observed in MIA PaCa-2 and Panc-1 cells. However, 
a comparative study between the two forms of the drugs 
i.e., the free form and c-SLN form showed approximately 
5 and 40-fold reductions in FA c-SLN and ASP c-SLN 
respectively in comparison to the free form of the drugs. 
Studies have been reported where drug loaded c-SLNs 
have exhibited better cytotoxicity profile in comparison 
to the free drug [3, 9]. This has been mainly attributed 
to the smaller particle size of the nanoparticles which 
increases the overall uptake of the drug. In order to vali-
date the efficacy of the combination regimen, apoptosis 
assay was conducted which determined the progression 
of a cancer cell from four different phases after the addi-
tion of the drug: living cell, early apoptotic cell, late apop-
totic cell and necrotic cells. These results are consistent 
with our findings in the cell viability assay.
Pancreatic tumor growth inhibition in in  vivo xeno-
graft mice model was observed by the oral administra-
tion of 75 and 25 mg/kg FA and ASP c-SLN combination, 
respectively, even though the effect was not statisti-
cally significant. In our previously published study [7], 
we used SLN encapsulated aspirin at a dose range of 
2–20  mg/kg, which demonstrated to be effective in 
suppressing the progression to pancreatic cancer in a 
hamster model. In this study, we used a conversion fac-
tor to calculate the dose given to the hamster to mouse 
which resulted in 25 mg/kg of ASP for the current study 
[46]. For FA, dose of 75  mg/kg used for these experi-
ments were deduced from publications demonstrating 
the use of higher doses than the proposed dose for the 
current studies [19, 47, 48]. Other in  vivo studies have 
found elevated levels of detoxifying enzymes in liver and 
colonic mucosa in rats fed with FA at the dose of 100 mg/
kg [17]. In the same study, FA reduced the incidence and 
multiplicity of intestinal azoxymethane-induced tumors 
after 35  weeks of oral administration of 250  mg FA/kg 
body weight/day.
IHC was performed to evaluate the molecular effect of 
FA +  ASP chemopreventive regimens on tumor reduc-
tion. This study showed decreased proliferation as doc-
umented by PCNA and MKI67 immunostaining, and 
increased apoptosis as documented by increased p21 
expression within tumors. Moreover, our results dem-
onstrate that the upregulation of p-ERK1/2 and p-RB 
proteins in FA + ASP treatment group compared to vehi-
cle control group. A number of studies have shown the 
importance of ERK signaling pathway in regulating apop-
tosis [6, 49, 50]. Although ERK pathway delivers a sur-
vival signal, recent studies and our previously published 
article on chemoprevention of aspirin have linked the 
activation of p-ERK with induction of apoptosis [51–53]. 
Our published study also presents a plausible mechanism 
by which aspirin, curcumin, sulforaphane (ACS) in com-
bination can induce apoptosis in pancreatic cancer cells 
through activation of the p-ERK1/2 signaling system. The 
ACS combination initiated p-ERK1/2 induction at 8  h, 
and the activity remained highly elevated through the 
remaining time period examined (48 h). It is important to 
note that there are different mechanisms of ERK activa-
tion, such as induction by growth factors could be rapid 
(occurring within minutes) and transient, which leads to 
cell proliferation and survival [54]. But persistent or sus-
tained p-ERK1/2 activation that lasts more than 12 h is 
involved in cell differentiation and death [55]. Our results 
support the pro-apoptotic role of p-ERK1/2 during 
FA + ASP treatment and are in agreement with previous 
studies [6, 51–53].
Conclusions
This study investigated the potential chemopreven-
tive effects of a combination of free FA and ASP as well 
as c-SLN encapsulated FA and ASP. We demonstrated 
for the first time that the FA and ASP c-SLN combina-
tion showed a synergistic inhibition of cell viability and 
induced apoptosis in MIA PaCa-2 and Panc-1 human 
pancreatic cancer cells. Further in  vivo studies dem-
onstrated the tumor shrinking capability of this c-SLN 
combination, even though this was not statistically sig-
nificant. Immunohistochemical studies indicate the pro-
apoptotic role of the regimen from significantly elevated 
protein expression. In conclusion, the preliminary data 
obtained from these studies provide a baseline on which 
further research is warranted to confirm this nanotech-
nology-based combination regimen as a potentially 
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viable chemopreventive tool in the fight against pancre-
atic cancer.
Methods
Cell lines and cell culture
Human pancreatic cancer cell lines MIA PaCa-2 and 
Panc-1 were obtained from American Type Culture Col-
lection (ATCC, Manassas, VA, USA). Cells were cultured 
in Dulbecco’s modified eagle medium (DMEM) sup-
plemented with 10 % fetal bovine serum (FBS), and 1 % 
penicillin–streptomycin at 37 °C in a 5 % CO2 humidified 
environment.
Reagents and antibodies
FA and ASP were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Stearic acid, Poloxamer 188, chitosan 
and lecithin was obtained from Spectrum Chemicals 
(Gardena, CA, USA). Dichloromethane (DCM) was 
obtained from Fisher Scientific (Houston, TX, USA). 
Sodium chloride was purchased from ChemCruz (Santa 
Cruz, CA, USA). Hydrochloric acid was purchased from 
Ricca Chemicals (Arlington, TX, USA). The primary 
antibodies against PCNA, p-ERK1/2 (Thr202/Tyr204), 
and  p-RB were obtained from Cell Signaling Technolo-
gies (Danvers, MA, USA). The MKI67 and p21 primary 
antibodies were purchased from Abcam (Cambridge, 
MA, USA).
Preparation of chitosan solid lipid nanoparticles (c‑SLNs)
FA and ASP c-SLNs were prepared using a hot melt oil-
in-water (o/w) emulsion technique (Fig.  7). Stearic acid 
was used as the lipid to make nanoparticle formulations. 
Briefly, 1 g of stearic acid was melted by heating at 70 °C. 
The drug (250  mg) was dissolved in 5  ml of DCM. The 
drug solution was then added to the melted stearic acid 
and heated until all DCM was evaporated. The water 
phase consisted of 2  % poloxamer solution which was 
heated to the same temperature as that of the oil phase. 
The volume ratio of oil phase to water phase was kept 
at 1:10. The oil phase was then added to the poloxamer 
solution drop wise using continuous high sheer homog-
enization and the mixture was further sonicated for 
30  s using an ultra-sonicator (Los Angeles, CA, USA) 
to create an o/w emulsion. The emulsion so formed was 
mixed with equal volume of 0.1 % chitosan dissolved in 
0.1 % acetic acid. The mixture of SLNs with chitosan was 
stirred for 2  h. The resulting chitosan-SLNs were cen-
trifuged and pellet was collected. The c-SLNs were lyo-
philized in a freeze dryer (Labconco, Kansas City, MO, 
USA) and subjected to particle size and encapsulation 
efficiency determination.
Measurement of particle size, encapsulation efficiency 
and zeta potential
The mean particle size (z-average) and polydispersity 
index (PDI) as a measure of the width of particle size and 
distribution was determined by photon correlation spec-
troscopy using Zetasizer (Nano ZS 90, Malvern Instru-
ments, Malvern, UK) at 25  °C and 90° scattering angle. 
The c-SLN formulation was diluted with nano-pure water 
to weaken opalescence before measurements. The sur-
face charge was assessed by measuring zeta potential of 
c-SLNs based on the Smoluchowski equation, using the 
same equipment at 25  °C with electric field strength of 
23 V/cm [54].
Determination of percentage encapsulation efficiency 
of FA and ASP c‑SLNs
Encapsulation efficiency was determined by dissolving 
10  mg of the c-SLN formulation in 10  ml acetonitrile. 
The drug was released from the lipid into acetonitrile and 
allowed to dissolve freely for 10 min in a sonicator after 
which it was filtered through a 0.45 µm filter. The result-
ing solution was further diluted with acetonitrile and 
was analyzed by using a Shimadzu LC-20 binary HPLC 
system (Columbia, MD, USA). Caffeine was used as the 
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Fig. 7 Schematic representation of chitosan solid lipid nanoparticle (c-SLN) formulation development
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internal standard. The entrapment efficiency was calcu-
lated using the following formula:
In vitro drug release from FA and ASP c‑SLNs
The cumulative release of ASP and CUR from c-SLNs 
was determined in both phosphate buffered saline (PBS), 
pH 6.8 and acidic medium, pH 1.6. Briefly, acidic medium 
composed of a mixture of sodium chloride (34.2  mM), 
lecithin (20 µM) and hydrochloric acid with pH adjusted 
to 1.6. Five mg of the c-SLNs were suspended in 50 ml of 
PBS/acidic medium and placed in an incubator at 37  °C 
with a shaking speed of 100 rpm. At predetermined time 
intervals (0, 0.5, 1, 2, 4, 6, 12, 24, 48, 72, 96  h), 1  ml of 
the buffer was withdrawn and replaced with equivalent 
volume of fresh buffer. All samples are centrifuged at 
5000 rpm for 10 min. The amount of released drug was 
analyzed using HPLC. The analysis was carried out in 
triplicate.
Cell viability assay
The cell viability assay was performed according to the 
manual included with the Promega Cell Titre 96 Aque-
ous MTS reagent (Madison, WI, USA). Briefly, 7.5 × 103 
cells were seeded in 96 well plates and treated with FA 
and ASP alone and in combination for a period of 72 h. 
On the last day of the incubation period, 20 % MTS and 
1 % of phenazine methosulfate (PMS) were added to the 
medium and incubated for 2 h at 37  °C and absorbance 
was measured at 490 nm. All the assays were performed 
in triplicate.
Flow cytometric analysis for apoptosis
The detection was performed according to the manual 
included with the Annexin V-fluorescein isothiocyanate 
(FITC) Vybrant Apoptosis assay kit #3 (Invitrogen, Grand 
Island, NY). Approximately 1  ×  105 MIA PaCa-2 and 
Panc-1 cells were seeded in six-well plates and treated 
with c-SLN modified FA and ASP alone and in combi-
nation at concentrations of 40 and 25 μM, respectively. 
After incubation for 48  h, cells were harvested, washed 
twice with ice-cold phosphate buffer saline (PBS), and 
then subjected to 5 µl of FITC Annexin V and 1 µl of the 
100 µg/ml PI. The samples were analyzed using Beckman 
Coulter Cytomics FC500.
Western blot analysis
MIA PaCa-2 and Panc-1 cells were treated with FA and 
ASP alone and in combination for 24 h. Cells were lysed 
in RIPA buffer and were fractionated on SDS–PAGE gels 













membranes were blocked with 2  % bovine serum albu-
min (BSA) in tris-buffered saline (TBS)-Tween 20 and 
probed with primary antibodies (1:1000 dilution) fol-
lowed by horseradish peroxidase (HRP)–labeled second-
ary antibodies (1:5000 dilutions). The blots were probed 
with the Super Signal West Pico Chemiluminescent sub-
strate (Thermo Scientific, Pittsburgh, PA, USA) to visual-
ize the immunoreactive bands.
Tumor xenograft model
The study was conducted on male severe combined 
immunodeficient (SCID) mice, 6 weeks old with an aver-
age body weight of ~20  g. All animals were maintained 
in pathogen-free sterile isolators and in a controlled 
atmosphere with a 12 h light to 12 h dark cycle accord-
ing to institutional guidelines. All studies were conducted 
as per protocol approved by the Western University of 
Health Sciences Institutional Animal Care and Use Com-
mittee and conformed to the “Principles of Laboratory 
Animal Care”. Mice were gavage daily with the chemo-
preventive regimen and weighed twice a week through-
out the experimental period. The human pancreatic 
cancer cells MIA PaCa-2 were grown in DMEM media 
containing 10  % FBS and harvested in HyQTase cell 
detachment solution (Hyclone). Cells were resuspended 
in saline at 1 ×  106 cells/0.1  ml volume, and placed on 
ice. SCID mice were injected with 0.1 ml of the cell sus-
pension subcutaneous on the right flank and observed 
daily for tumor growth. After transplantation, tumor size 
was measured using calipers, and the tumor volume was 
estimated according to the following formula: tumor vol-
ume (mm3) = L × W2, where L is the length and W is the 
width. After 5  weeks, mice were sacrificed and tumors 
were excised immediately.
FA + ASP c‑SLN treatment regimen
As indicated in Table 2, this set consisted of five groups 
(T1–T5) of 4 mice per group. The treatment groups 
T3-T5 received FA c-SLN, ASP c-SLN alone and a combi-
nation of FA + ASP c-SLN regimen daily via oral gavage, 
Table 2 Treatment plan showing group of  mice treated 
with c-SLN modified FA, and ASP
ASP aspirin, FA ferulic acid, c-SLN chitosan solid lipid nanoparticle
Groups Number  
of mice
Treatment plan Dose 
(mg/kg)
T1 4 Saline (control) 0
T2 4 Blank c-SLN (vehicle  
control; no drug)
100
T3 4 FA c-SLN 75
T4 4 ASP c-SLN 25
T5 4 FA + ASP c-SLN  
combination
75 + 25
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respectively. Treatment started the day after tumor cell 
implantation and continued every 24 h for 5 weeks. The 
T1 group served as control and received 0.1  ml PBS, 
and T2 group received blank c-SLN serving as vehicle 
control. The dose selected for FA c-SLN and ASP c-SLN 
regimens were 75 and 25 mg/kg respectively, which was 
determined based on current evidence in literature [19, 
48, 55].
Histological examination
All organs of the thoracic and abdominal cavities were 
carefully examined in situ macroscopically after euthani-
zation. The MIA PaCa-2 tumor tissue was fixed in 10 % 
phosphate-buffered formalin for 24 h. The formalin-fixed 
pancreatic tumor was cut into small pieces at 2 cm inter-
vals, and 5 μm thick sections were processed.
Immunohistochemistry (IHC)
Paraffin-embedded sections of pancreatic tumor tissue 
were deparaffinized, rehydrated, and heated in citrate 
buffer (pH 6.0) for 20  min for antigen retrieval. Endog-
enous peroxidase activity was quenched by incubating 
the slides in 3 % hydrogen peroxide, followed by washing 
in PBS-Tween 20. Subsequently, 5 % normal goat serum 
blocking buffer was applied. The blocking buffer was 
removed after 1  h of incubation in humidified chamber 
and primary antibody was added to the slides, incubated 
overnight at 4  °C. The horseradish peroxidase (HRP)-
labelled secondary antibody (Cell Signaling Technolo-
gies) was then added and incubated for 90 min at room 
temperature. The section was developed with ImmPACT 
DAB peroxidase substrate kit (Vector Labs, Burlingame, 
CA, USA).
Evaluation of staining
Antibody stained tissues were assessed using scoring 
system based on the Quickscore method [56]. For IHC 
staining, the protein stained in brown color was consid-
ered labeled/positive and nuclear staining in blue as unla-
beled/negative staining. Briefly, the proportion of positive 
cells were estimated and given a score on a scale of 1–4 
(1 = 0–10 %; 2 = 11–30 %; 3 = 31–59 %; 4 = 60–100 %). 
The intensity of the staining was estimated and given a 
score from 1–4 (1 = no staining; 2 = weak; 3 = interme-
diate; and 4 =  strong staining). A score was then calcu-
lated by multiplying the percentage of positive cells score 
by the intensity score, to yield a minimum value of 1 and 
a maximum value of 16.
Statistical analysis
Results were expressed as mean  ±  SEM. A one-way 
ANOVA followed by Dunnett’s multiple comparison test 
post hoc analysis using Graphpad prism software (La 
Jolla, CA, USA) was done to analyze and compare the 
results. A probability value of ≤0.05  % was considered 
significant.
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